Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Update

Lucid Diagnostics Inc. (NASDAQ:LUCD) was the target of a significant increase in short interest in January. As of January 30th, there was short interest totaling 7,014,153 shares, an increase of 84.7% from the January 15th total of 3,797,518 shares. Currently, 5.5% of the shares of the stock are sold short. Based on an average daily volume of 4,345,378 shares, the short-interest ratio is presently 1.6 days. Based on an average daily volume of 4,345,378 shares, the short-interest ratio is presently 1.6 days. Currently, 5.5% of the shares of the stock are sold short.

Lucid Diagnostics Trading Up 9.0%

LUCD stock traded up $0.11 during mid-day trading on Friday, reaching $1.33. The company’s stock had a trading volume of 881,788 shares, compared to its average volume of 1,932,297. The company’s 50 day moving average is $1.16 and its two-hundred day moving average is $1.12. Lucid Diagnostics has a fifty-two week low of $0.95 and a fifty-two week high of $1.80. The stock has a market cap of $183.12 million, a PE ratio of -1.28 and a beta of 1.22.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $1.21 million during the quarter, compared to analyst estimates of $1.35 million. On average, analysts forecast that Lucid Diagnostics will post -0.84 earnings per share for the current fiscal year.

Institutional Trading of Lucid Diagnostics

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Lucid Diagnostics by 28.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 224,921 shares of the company’s stock worth $245,000 after acquiring an additional 50,053 shares during the period. State Street Corp grew its holdings in shares of Lucid Diagnostics by 32.9% in the fourth quarter. State Street Corp now owns 1,352,955 shares of the company’s stock valued at $1,475,000 after purchasing an additional 335,168 shares during the period. Wells Fargo & Company MN increased its position in Lucid Diagnostics by 28.7% during the fourth quarter. Wells Fargo & Company MN now owns 919,479 shares of the company’s stock worth $1,002,000 after purchasing an additional 205,166 shares during the last quarter. Jane Street Group LLC increased its position in Lucid Diagnostics by 1,123.4% during the fourth quarter. Jane Street Group LLC now owns 362,615 shares of the company’s stock worth $395,000 after purchasing an additional 332,975 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Lucid Diagnostics by 181.5% during the fourth quarter. Renaissance Technologies LLC now owns 826,527 shares of the company’s stock worth $901,000 after purchasing an additional 532,894 shares during the period. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on LUCD shares. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Wall Street Zen lowered Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday, November 13th. Finally, Ascendiant Capital Markets lifted their price target on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $3.94.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.